Formation of an aberrant, chimeric Bcr-Abl protein is the hallmark of Philadelphia (Ph) chromosome-positive leukemias. The Bcr-Abl protein, as well as its normal cellular counterpartsAbl and Bcr -are intracellular molecules with postulated roles in a variety of critical biologic functions. In this study, we demonstrate the existence of autoantibodies against these proteins. Plasma from 18 of 31 individuals (58%), including 14 of 20 Ph-positive CML patients (70%), two of four normal volunteers (50%), and two of seven patients with Ph-negative leukemia (29%) recognized p210
Introduction
The Philadelphia chromosome (Ph) is the molecular hallmark of chronic myelogenous leukemia (CML) and also occurs in some cases of acute leukemia. It represents a reciprocal translocation between the long arms of chromosomes 9 and 22 (t(9;22) (q34;q11)). At the molecular level, this translocation transposes the ABL gene from chromosome 9 and juxtaposes it to various regions within the disrupted 5′ end of the BCR gene on chromosome 22. [1] [2] [3] [4] These abnormal configurations result in the creation of chimeric BCR-ABL genes which encode hybrid proteins designated p210
Bcr-Abl or p190
Bcr-Abl . [1] [2] [3] [4] [5] In the p210 Bcr-Abl -encoding BCR-ABL transcript, either exon b2 or exon b3 of the major breakpoint cluster region (bcr) lying in the central region of the BCR is coupled to ABL exon 2 (b2-a2 or b3-a2 junction); in the p190
Bcr-Abl -encoding transcript, the first exon of the BCR gene is coupled to ABL exon 2.
4 p210 Bcr-Abl and p190 Bcr-Abl are believed to be important in the genesis of CML and Ph-positive acute leukemia, respectively.
Several lines of evidence support the existence of an immunomodulatory mechanism in CML. For instance, CML patients who receive an allogeneic transplant after T lymphocyte depletion of donor marrow have a higher incidence of relapse. 6, 7 Interestingly, some peptides from the p210
Bcr-Abl can bind major histocompatibility (MHC) molecules, and can induce MHC-restricted cytotoxic T lymphocyte responses. [8] [9] [10] In addition, the lymphocytes from chronic phase CML patients proliferate upon co-culture with autologous leukemia cells. 11 Finally, during the course of interferon-␣ therapy, there is a steady increase in natural killer (NK) cell activity 12 and lymphokine-activated killer cell generation. 13 To date, however, a role for B cells or antibodies in CML-related immune phenomena has not been demonstrated. In the current study, we show that plasma from both Ph-positive and Ph-negative leukemia patients and from healthy volunteers can detect p210
Bcr-Abl , p145
Abl and, to a lesser extent, p160
Bcr .
Materials and methods

Cell lines
The following cell lines were used: (1) K562 cells 14 (Ph-positive CML blast crisis line with b3-a2 junction) (American Type Culture Collection (ATCC), Rochester, MD, USA) maintained in RPMI-1640 supplemented with 10% fetal calf serum (Hyclone, Logan, UT, USA) at 37°C in humidified air containing 5% CO 2 ; (2) KBM-7 cells 15 (Ph-positive CML cell line with b2-a2 junction) maintained in Iscove's modification of Dulbecco's medium with 25% fetal calf serum (GIBCO, New York, NY, USA); (3) BV173 cells 16 (CML lymploid blast crisis line with b2-a2 junction) maintained in RPMI-1640 with 15% fetal calf serum; and (4) KG1 cells (ATCC, Rockville, MD, USA) (Ph-negative, Bcr-Abl-negative myeloid leukemia line) maintained in RPMI (with 10% fetal calf serum).
Leukemia
Antibodies
Polyclonal and monoclonal anti-Abl and anti-Bcr antibody were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated donkey antirabbit immunoglobulin and goat anti-mouse immunoglobulin were purchased from Amersham (Arlington Heights, IL, USA). Isotypic controls for the above antibodies were purchased from DAKO Corporation (Carpinteria, CA, USA).
Immunoprecipitation followed by immunoblotting (Western blotting)
Immunoprecipitation followed by Western blotting was used to determine if human plasma contained antibodies capable of detecting Bcr, Abl and p210
Bcr-Abl proteins. Four hundred l of Bcr-Abl-positive and -negative cell line lysates prepared as noted above was diluted with 2× immunoprecipitation buffer (1× buffer contains 1% Triton 100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2 mM sodium vanadate, 0.2 mM PMSF, 0.5% NP-40) and incubated with 600 l plasma from patients or normal donors. After overnight incubation at 4°C, 50 l protein G-Sepharose beads (Santa Cruz Biotechnologies) were added to the above mixture and incubated for 1 h at 4°C. The immune complexes bound to the beads were washed three times with cold 1× immunoprecipitation buffer (described above) and 30 l 2x denaturing lysis buffer (more commonly called sample buffer or loading buffer; 1× buffer contains 125 mM Tris pH 6.8, 2% SDS, 5% glycerol, 0.003% bromophenol blue, 1% ␤-mercaptoethanol) was added to each tube and boiled at 100°C for 5 min. This was followed by centrifugation at 12 000 g. The resulting supernatants (15 l) were then loaded on 5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins transferred at 30 V on to Immobilon-P transfer membrane (Millipore, Burlington, MA, USA) overnight at 4°C. The blots were blocked with 5% bovine serum albumin for 2 h at room temperature and incubated with a suitable primary antibody at room temperature for 1 h. After washing the membrane for 30 min with TBST (10 mM Tris-HCl, pH 7.5, 100 mM NaC1, 0.1% Tween-20), the blots were incubated with a suitable secondary antibody at room temperature for 1 h. The blots were washed again with TBST and visualized with electrochemiluminescent kit (Amersham Life Science, Cleveland, OH, USA). Controls for each experiment included isotypic antibody (control for monoclonal antibody) and preimmune sera (for polyclonal antibody).
BCR, ABL and BCR-ABL: Construction of transfer vectors and purification in Autographa californica nuclear polyhedrosis virus (AcNPV) infected insect cells
Purified Bcr, Abl and Bcr-Abl were used as target proteins for detection by patient-derived serum antibodies. Baculovirus vectors of p210 bcr/abl were made from the digests of the pGEM4 [0]p210 plasmid (kindly donated by Dr AM Pendergast, Duke University) at the EcoRI site, and the fragment containing the complete p210
Bcr-Abl -encoding gene plus the 5′ untranslated sequence are then inserted from the EcoRI to the HindIII site upstream of the 6× histidine/thrombin cleavage site containing pAcGHLT-C Baculovirus transfer vector (PharMingen, San Diego, CA, USA). Proteins expressed are fused with 6× histidine and a thrombin cleavage site at the C-terminal region.
Transfer of the p210 Bcr-Abl gene from recombinant plasmids to Autographa californica nuclear polyhedrosis virus (AcNPV) by cotransfection was performed by using the Baculovirus Expression Kit (PharMingen) according to the manufacturer's instructions. The AcNPV particles were expressed in Sf9 cells (PharMingen). Within 3 days of cotransfection, cells were harvested and disrupted with insect cell lysis medium (PharMingen), and the expressed p210
Bcr-Abl was purified by chelate affinity chromatography with a Ni-NTA agarose (Qiagen, Santa Clarita, CA, USA). The 6× histidine site was cleaved with thrombin (PharMingen). The free proteins were separated by preparative electrophoresis, reverse phase HPLC, and immunoaffinity chromatography. Purity of the p210 bcr/abl by electrophoresis and HPLC was estimated to be у99%.
In parallel experiments employing the methods similar to those described above, we also inserted the DNA sequences of BCR and ABL into the Baculovirus system in order to obtain both Abl and Bcr proteins for this study. For Abl, a 3.5-kb DNA fragment containing the entire coding sequence of human ABL was purified as an EcoRI fragment from the plasmid pSG5 (kindly provided by Dr R Arlinghaus, MD Anderson Cancer Center, Houston, TX, USA). This fragment was cloned directly into the EcoRI site of the baculovirus transfer vector pAcG3X (PharMingen). The construct containing the ABL gene in the correct orientation was designated pAcG3X-abl. Similarly, DNA fragments containing the entire coding sequence of human BCR were purified as BamHI fragments from the pSG5 plasmid (donated by Dr R Arlinghaus) and inserted into the BamHI site of the vector pAcG3X (PharMingen). The construct containing the BCR gene in the correct orientation was designated as pAcG3X-bcr. Separate cotransfection of 4 g of pAcG3X-abl and the pAcG3X-bcr with 1 g of linearized BaculoGold Baculovirus DNA (PharMingen) were performed according to the manufacturer's instructions. Separate cultures of Sf9 cells were transfected with resulting combined viral DNA and plasmids using a calcium phosphate method accompanying the transfection kit (PharMingen). Cells were lysed 3 days post infection and the extracts were analyzed by immunoprecipitation methods as described above.
Results
Patient characteristics
Twenty patients with Philadelphia-positive CML were tested. These included 11 men and 9 women. Median age of the patients was 51 years (range, 31-67 years). Sixteen of the patients were considered to be in chronic phase, two were in accelerated phase, and two were in blast crisis. According to analysis by polymerase chain reaction, 13 patients had a p210
Bcr-Abl derived from a b 3 a 2 junction mRNA and seven had a b 2 a 2 transcript. Four patients with Philadelphia-negative, Bcr-Abl-negative hematologic malignancies were also analyzed. Their diagnoses were essential thrombocythemia (n = 1,) myelofibrosis (n = 1), and acute myelogenous leukemia (n = 2). Seven healthy controls were also analyzed. These included four men and three women with a median age of 42 years (range, 25-65 years). Human plasma recognizes p210 Bcr-Abl Plasma from 18 of 31 (58%) individuals was able to immunoprecipitate p210
Bcr-Abl
. These included 14 of 20 (70%) patients with Ph-positive CML, (including 12 patients in chronic phase, one in accelerated phase, and one in blast crisis) two of four (50%) with Ph-negative hematologic malignancies, and two of seven (29%) normal subjects ( Table 1, Figures 1 and 2) . In all cases but one (Figure 1 , CML No. 9), plasma which recognized p210
Bcr-Abl with a b2a2 junction also recognized p210
Bcr-Abl with a b 3 a 2 junction. There was no difference on plasma reactivity of CML patients bearing a b 3 a 2 vs a b 2 a 2 junction (P Ͻ 0.05).
Human plasma recognizes both Bcr and Abl proteins
Further experiments were performed in order to determine if human plasma was able to specifically detect p210
Bcr-Abl or if Bcr-Abl was being detected because of the presence of anti-Bcr or anti-Abl antibodies. Figures 3 and 4 demonstrate that human plasma was able to detect Baculovirus-expressed Abl protein (Figure 3 ) and, to a lesser extent, Bcr protein ( Figure 4) . Overall, in all 18 patients whose plasma detected p210
Bcr-Abl , reactivity to p145
Abl was demonstrated. In addition, plasma from four of these individuals was able to recognize Bcr protein (Table 1) .
Discussion
Natural antibodies directed against a wide range of self antigens are detected in normal sera. 17 These natural autoantibodies are of two types: monoreactive and polyreactive. 18, 19 Monoreactive antibodies react with a single known antigen and are generally of high affinity. In contrast, polyreactive antibodies are usually of low affinity, bind to many different self and nonself antigens, and are, for the most part, of the IgM isotype (although 25-50% of IgG may be polyreactive). 19 The physiologic role of these autoantibodies is unknown. Yet, even in the case of the polyreactive antibodies, engagement in normal immune regulatory functions, eg clearance of self antigens by opsonization and phagocytosis, has been established. 20 Autoantibodies may also be pathogenic as in the case of autoimmune diseases. Which biologic processes provoke natural autoantibodies to switch from harmonically existing parts of the immune repertoire to disease participants remains unclear.
Although antibodies to autoantigens have long been known to play a role in autoimmune disorders, it is only recently that Immunoprecipitation followed by immunoblotting. Plasma from patients with CML (CML #1 and #3) and other leukemias (Ph(−) #1) were used to immunoprecipitate lysates from Ph(+) cell lines with b2a2 (BV173) or b3a2 (KBM-7) junction, or Ph(−) cell line (KG1). A Western blot was used to identify the immunoprecipitate using a monoclonal anti-Bcr antibody (panel a) or an isotypic control sera (panel b).
Figure 3
Immunoprecipitation followed by immunoblotting. Plasma from patients with CML (CML #5, #13), or normal controls (Normal #2) were used to immunoprecipitate lysates from Sf9 cells untransfected (Sf9) or transfected with ABL (Abl-Sf9). Control immunoprecipitations with monoclonal anti-Abl sera and isotypic control (IgG) were also performed. The immunoprecipitate was identified on a Western blot using a monoclonal anti-Abl sera.
they have been implicated in other illnesses such as cancer. Over the last few years, antibody (IgG) immune responses to the proto-oncogenic p185 HER-2/neu found on the cell surface have been demonstrated in breast cancer patients as well as in normal subjects. 21 Antibody titer correlated with overexpression of HER-2/neu, 22 but the relationship between these titers and outcome has not yet been determined. Antibodies to intracellular, cancer-related proteins such as Myc, Myb and p53 have also been documented. [23] [24] [25] [26] [27] Indeed, about 9-15% of breast cancer patients have been found to have circulating antibodies against p53, 23, 24 and children with a wide variety of cancers have a similar frequency of p53 antibodies. 28 In the current study, we demonstrate that plasma derived from 14 of 20 Ph-positive CML patients as well as from two of four Ph-negative leukemics and from two of seven normal controls can detect p210
Bcr-Abl . In all 18 cases in which p210
Bcr-Abl was detected, plasma was able to recognize the normal Abl protein. In four of these 18 cases, plasma also recognized the normal Bcr protein. Taken together, these data suggest that it is unlikely that recognition of p210
Bcr-Abl occurs because of a Bcr-Abl-specific epitope. Rather, recognition appears to be attributable to reactivity with epitopes found in normal Abl and/or normal Bcr proteins. Immunoprecipitation followed by immunoblotting. Plasma from patients with Ph-negative leukemia (Ph(−) #1) and normal controls (Normal #2) were used to immunoprecipitate lysates from Sf9 cells untransfected (Sf9) or transfected with BCR (Bcr-Sf9). Control immunoprecipitations with monoclonal anti-Bcr sera and isotypic control were also performed. The immunoprecipitate was identified on a Western blot using a monoclonal anti-Bcr sera.
How such autoantibodies might be created is a matter of debate. It is possible that autoantibodies to normally sequestered intracellular proteins form for any one of several reasons: (1) the release of excessive antigen during cell death resulting in loss of tolerance; (2) unmasking or a change in epitopes during cellular necrosis/apoptosis; or (3) crossreaction with autoantigens by antibodies formed to non-self proteins. Perhaps the best known example of the latter is seen in rheumatic fever, a disease precipitated by the epitope mimicry between group A streptococcus and heart tissue (reviewed in Refs 29 and 30). In cancer, any of these mechanisms could be operative. However, in addition, antibody could form in response to a specific protein determinant altered by mutation or translocation, a situation which would be plausible with eliciting proteins such as p53 or Bcr-Abl, respectively. The current literature, while suggesting several important clues as to the mechanism of production of such autoantibodies, provides an incomplete picture. For instance, generation of humoral immunity against specific epitopes is supported by the finding that p53 antibodies are more common in patients who harbor mutations within exons 5 and 6. 23 On the other hand, the antibodies themselves recognize both wild-type p53 and a variety of mutants and are specific for carboxy and amino terminal regions devoid of mutations. 24 Therefore, overall, the loss of tolerance hypothesis is better supported by the experimental data. The situation is, however, complicated by data showing that p53 antibody-eliciting tumors contain complexes between p53 and a 70 kDa heat shock protein, whereas none of the antibody-negative tumors contain this complex. 23 The latter results implicate a 70 kDa heat shock protein in the antigenic presentation of p53. Some of the emerging concepts regarding antinuclear autoantibodies (ANAs) and their target autoantigens may also be relevant. [31] [32] [33] ANAs are associated with systemic autoimmune diseases. Interestingly, ANAs recognize highly conserved, conformation-dependent epitopes which may include discontinuous sequences (rather than linear sequences of the primary structure) associated with active regions of targeted subcellular particles. The antigens are often components of macromolecular complexes 31 (reviewed in Ref. 32 ). The question remains as to how these intracellular particles become exposed to the immune system and rendered capable of eliciting a humoral response. Apoptosis or cellular necrosis could account for their release. Indeed, it has been suggested that, since a subset of nuclear antigens is cleaved by proteases during programmed cell death, these antigens may undergo changes in their molecular structure during apoptosis that expose previously immunocryptic epitopes (reviewed in Ref. 32) .
Plasma reactivity to Abl, Bcr and Bcr-Abl proteins could reflect an immunosurveillance mechanism and as such might be exploitable as a tool for early diagnosis or monitoring of treatment impact. This would be the case if antibody level or the specific epitopes recognized prove to be preferentially distributed in patients with certain disease features or therapeutic responses. In the case of breast cancer, there is already preliminary documentation of a correlation between antibodies to p53 and poor prognostic features such as high histologic grade and absence of hormone receptors. [23] [24] [25] In our study, the finding that plasma reactivity to normal Abl is present in healthy controls mitigates against the utility of detection of itself as a prognostic variable. The percentage of control plasma that reacted to Abl was lower than that of CML patients, but these differences did not reach statistical significance (Table 1) . However, the possibility that a larger cohort of patients and controls might yield a significant difference or, alternatively, that antibody titer and/or specific epitope recognition differs between patient groups is being examined.
Cancer-related autoantibodies to intracellular proteins may reflect an epiphenomenon of immune regulation. Alternatively, the antibodies could conceivably have a direct role in disease modulation. Indeed, recent data demonstrating that antibodies (eg anti-DsDNA and anti-U1 ribonucleoprotein antibodies) can gain entry to even the intact nucleus [34] [35] [36] indicates that antibodies to totally sequestered proteins can be biologically active. Although the full ramifications of this phenomenon on cell function remain unclear, anti-U1 ribonucleoprotein antibodies which penetrate live mononuclear cells cause apoptosis. 37 The role of plasma reactivity to Bcr-Abl, Abl and Bcr in Phpositive leukemias merits further exploration. That the immune system can mediate an antileukemic response in CML is already strongly suggested by the clinical observation that allogeneic transplant recipients whose CML has relapsed can be reinduced into remission by donor lymphocyte Leukemia infusions. [38] [39] [40] The mechanisms operating in this form of cellular immunotherapy probably involve antigen presentation and recognition resulting in T cell activation and accessory cell recruitment followed by cytotoxicity. (It is known that T cells recognize antigens that have been processed and presented in the context of major histocompatibility complex (MHC) molecules (reviewed in Ref. 40) ). The antigens responsible for the immune effect are unknown, although it is possible that a Bcr-Abl-derived peptide is the target. 41 Additional evidence for a role for the immune system in CML is derived from the observation that interferon-treated CML patients may remain in long-term continuous cytogenetic remission despite the presence of residual, albeit dormant, BCR-ABL-positive colony-forming cells that should have the potential to repopulate the bone marrow. 42 As can be surmised from the above discussion, to date, it has been T lymphocytes which have been implicated in the generation of an immune response in CML. This field is, however, in a relatively nascent stage. In light of our findings, a role for B cells in CML-related immunity is also conceivable. Other questions of interest relate to the mechanism responsible for formation of these antibodies. Experiments to determine whether or not Abl-derived peptides are presented on the cell surface are in progress. Furthermore, identification of the epitopes recognized and their relationship, if any, to the motifs recognized by T lymphocytes in CML is underway. 43 These investigations should expand our understanding of the role of the humoral in addition to the cellular immune system in modulating the outcome in CML, and may be relevant to the emerging interest in development of vaccines for the treatment of this disorder.
